Table 1.
Receptor modulation by cannabinoids and studies outlining their potential involvement in disease treatment.
| Receptor | Cannabinoid | Disease/Interaction | Study Type | Reference |
|---|---|---|---|---|
| CB1 | Anandamide | Appetite | Murine models | [173,174] |
| Met-F-AEA | Thyroid cancer | in vitro human | [175] | |
| THCB (PA) | Pain | Murine models | [176] | |
| THC (PA) | Epilepsy | Murine models | [177] | |
| Sleep | Various studies | [178] | ||
| THCP (Ag) | Pain, anxiety, hypothermia, catalepsy | Murine models | [22] | |
| THCV (^) | Pain, anxiety, hypothermia, catalepsy | Murine models | [179,180] | |
| Parkinson’s disease | Murine models | [181] | ||
| Obesity | Murine models | [182] | ||
| Epilepsy | in vitro murine | [183] | ||
| THC, WIN55,212-2, CP55, 940 |
Emesis | Animal models | [184,185,186,187,188] | |
| WIN55,212-2 | Parkinson’s disease | Murine model | [189] | |
| Prostate cancer | in vitro human | [190] | ||
| WIN55,212-2, JWH-133 | Breast, lung cancer | in vitro human | [191,192] | |
| CB2 | CBC (Ag) | Inflammation | in vitro models | [193] |
| CBG (PA) | Inflammatory bowel disease | Murine models | [194] | |
| HU-308, AM630 | Parkinson’s disease | Murine models | [195,196] | |
| THCP (Ag) | Pain, anxiety, hypothermia, catalepsy | Murine models | [22] | |
| THCV (^) | Inflammation | Murine models | [180] | |
| CB2 | THCV (^) | Parkinson’s disease | Murine models | [181] |
| Pain, anxiety, hypothermia, catalepsy | Murine models | [179] | ||
| WIN55,212-2 | Prostate cancer | in vitro human | [190] | |
| WIN55,212-2, JWH-133 | Breast, lung cancer | in vitro human | [191,192] | |
| GPR55 | Abnormal CBD | Parkinson’s disease | Murine models | [103] |
| GPR55 | Abnormal CBD | Pain/arthritis | Murine models | [105] |
| CBD (An) | Gastrointestinal disorders | Canine, murine models | [93,94,95,96] | |
| CBDV (An) | Rett syndrome | Murine models | [197] | |
| LPI inhibitor | in vitro | [198] | ||
| THC, anandamide, JWH015 | Pain | in vitro HEK239 | [97] | |
| TRPV1 | CBDV (Ag) | Anti-seizure | in vitro HEK239 | [199] |
| CBG (Ag), CBGV, CBD (Ag), CBDV (Ag), THCV (Ag) | Receptor desensitisation | in vitro HEK239 | [200] | |
| TRPV2 | CBD (Ag), CBGV, CBG (Ag), THCV (Ag), CBDV (Ag), CBN (Ag) | Receptor desensitisation | in vitro HEK239 | [200] |
| TRPV3 | CBGV, CBGA (Ag) | Receptor desensitisation | in vitro HEK239 | [201] |
| TRPV4 | CBGV, CBGA, CBN, CBG | Receptor desensitisation | in vitro HEK239 | [201] |
| TRPM8 | CBG (An), CBC (An), CBD (An), CBDV (An), THC (An), THCA (An) | Colorectal cancer | in vitro model | [200,202,203] |
| TRPA1 | CBC (Ag), CBN (Ag), THC (Ag), THCV (Ag), THCA (Ag), CBDA, CBG (Ag) | Receptor desensitisation | in vitro HEK239 | [200,202] |
| CBDV (Ag) | Ulcerative colitis | in vitro human | [204] | |
| Muscular dystrophy | in vitro studies | [205] |
PA = Partial Agonist, Ag = Agonist, ^ = Dose Dependent, An = Antagonist.